The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab as Maintenance Therapy for Difficult-to-Treat SLE

Rituximab as Maintenance Therapy for Difficult-to-Treat SLE

September 1, 2020 • By Mary Beth Nierengarten

  • Tweet
  • Email
Print-Friendly Version / Save PDF

For patients with difficult-to-treat systemic lupus erythematosus (SLE), regular treatment with rituximab may offer a way to maintain disease remission, according to research published in Arthritis & Rheumatology.1 Patients with severe disease localization, in particular, may benefit from rituximab maintenance therapy if traditional therapy, such as glucocorticoids and methotrexate, is ineffective or not well tolerated, or if other licensed biologics are unavailable or not indicated.

You Might Also Like
  • Rituximab May Help Pediatric Patients with SLE
  • Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
  • Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?
Also By This Author
  • ACR’s 2017 Advocacy Successes

The study from Cassia et al. examined the efficacy and safety of rituximab in SLE patients, with a particular focus on a subgroup of patients treated with maintenance rituximab to prevent relapse.

Dr. Alberici

“Our study is the first focusing on a cohort of SLE patients treated with rituximab-based maintenance treatment with the aim of relapse prevention,” says Federico Alberici, MD, PhD, associate professor-consultant in Renal Medicine University of Brescia, Brescia, Italy, and the study’s corresponding author and coordinator.

Dr. Alberici emphasized the need to improve remission in SLE patients as a key phase of disease management, as well as the need to find an effective maintenance therapy to achieve this outcome. Traditional drugs, he says, may provide some disease control, but flares remain common. Although biologic therapy, in particular belimumab, is effective at controlling flares in subsets of SLE patients with mucocutaneous and articular involvement, belimumab is not currently indicated for patients with active, severe, disease localization.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In the study, the researchers retrospectively assessed the efficacy and safety of rituximab in 147 SLE patients at four centers. Sixty-seven of the 147 patients were treated with a single course of rituximab, receiving their doses within a single month given two weeks apart or over four consecutive weeks. Eighty patients were treated with rituximab maintenance therapy, receiving at least three single-rituximab courses, with an interval of four to eight months between consecutive treatment courses. Patients were stratified into four groups based on disease severity at baseline: mild, moderate, severe and drug sparing. The drug-sparing group included patients for whom rituximab was being used to reduce exposure to other drugs with an unfavorable balance of potential benefits and toxicity.

To assess disease activity, the investigators used the European Consensus Lupus Activity Measurement (ECLAM) and the physician’s assessment (i.e., 0 = no sign of active SLE, 1 = mild disease activity and 2 = severe disease activity). They also measured changes in the immunosuppressive drugs used by patients in association with rituximab.

Response to the first course of rituximab was assessed after six months. The study defined a complete response as a physician’s assessment score of 0 or 1, a reduction of at least 50% in ECLAM score and at a least 25% decrease from baseline in immune-modulating therapy dosage. A partial response was defined as a physician’s assessment score greater than 0, a 25–50% reduction in ECLAM score and a 0–25% reduction in immune-modulating therapy dosage. Any other response was defined as treatment failure.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, SLE (Lupus) Tagged With: Arthritis & Rheumatology, maintenance therapy, rituximab

You Might Also Like:
  • Rituximab May Help Pediatric Patients with SLE
  • Longer Rituximab Therapy Boosts Remission in ANCA-Associated Vasculitis
  • Rituximab Maintenance Study: Is Fixed-Schedule or Tailored Dosing Best?
  • California Rheumatology Alliance 2013 Meeting: Rheumatologists Advised to Drop Prednisone Maintenance Therapy in Lupus Patients

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.